Press Releases

  • Mar. 29, 2021 Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology

    NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Mar. 24, 2021 Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing

    NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and… Read more »

  • Mar. 22, 2021 Bioasis Technologies Inc. Announces Warrant Extension and Repricing

    NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ?™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers… Read more »

  • Mar. 8, 2021 Bioasis to Attend and Present at Upcoming Investor and Industry Conferences

    NEW HAVEN, Conn., March 08, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »

  • Feb. 10, 2021 Bioasis Announces Shares for Debt Transaction

    NEW HAVEN, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers… Read more »

  • Jan. 29, 2021 Bioasis Announces $200,000 Non-Brokered Private Placement

    GUILFORD, Conn., Jan. 29, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and… Read more »

  • Jan. 27, 2021 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020

    GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more »

  • Jan. 22, 2021 Bioasis Announces Stock Option Grant

    GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative… Read more »

  • Jan. 4, 2021 Bioasis to Present at Upcoming Industry Conferences

    GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high… Read more »

  • Dec. 10, 2020 Bioasis Announces Annual General Meeting Results

    GUILFORD, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical… Read more »